• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by InflaRx N.V. (Amendment)

    2/14/22 11:23:48 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IFRX alert in real time by email
    SC 13G/A 1 greatpoint-ifrx123121a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    InflaRx N.V.

    (Name of Issuer)

     

    Common Shares, nominal value €0.12 per share

    (Title of Class of Securities)

     

    N44821101

    (CUSIP Number)

     

     

    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     


     

    CUSIP No.  N44821101
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Great Point Partners, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     

    0

    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%1
    12
    TYPE OF REPORTING PERSON
     
    IA/OO

    1 Based on a total of 44,186,280 shares of common stock outstanding.

     


     

    CUSIP No.  N44821101
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Dr. Jeffrey R. Jay, M.D.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%1
    12
    TYPE OF REPORTING PERSON
     
    IN/HC

    1 Based on a total of 44,186,280 shares of common stock outstanding.

     


     

    CUSIP No.  N44821101
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Mr. Ortav Yehudai
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%1
    12
    TYPE OF REPORTING PERSON
     
    IN/HC

    1 Based on a total of 44,186,280 shares of common stock outstanding.

     


     

     

    CUSIP No. N44821101
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    InflaRx N.V.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    Winzerlaer Str. 2

    07745 Jena, Germany

     

    Item 2.(a) Names of Persons Filing:

    Great Point Partners, LLC

    Dr. Jeffrey R. Jay, M.D.

    Mr. Ortav Yehudai

     

    The Reporting Persons have entered into a Joint Filing Agreement, dated March 8, 2021, a copy of which is filed with this Schedule 13G/A as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

     

    Item 2.(b) Address of Principal Business Office:

    The address of the principal business office of each of the Reporting Persons is

     

    165 Mason Street, 3rd Floor

    Greenwich, CT 06830

     

    Item 2.(c) Citizenship:

    Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. Ortav Yehudai is a citizen of the United States.

      

    Item 2.(d) Title of Class of Securities

    Common Shares, nominal value €0.12 per share (the “common stock”)

     

    Item 2.(e) CUSIP No.:

    N44821101

     

    CUSIP No.  N44821101
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. N44821101
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    1. Great Point Partners, LLC

    (a) Amount beneficially owned: 0 

    (b) Percent of class: 0%1 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    2. Dr. Jeffrey R. Jay, M.D.

    (a) Amount beneficially owned: 0 

    (b) Percent of class: 0%1 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    3. Mr. Ortav Yehudai

    (a) Amount beneficially owned: 0 

    (b) Percent of class: 0%1 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0 

    1 Based on a total of 44,186,280 shares of common stock outstanding.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    See Item 4.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. N44821101
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

     

     

     

    Great Point Partners, LLC

           
      By:  /s/ Dr. Jeffrey R. Jay, M.D.
        Dr. Jeffrey R. Jay, M.D., as Senior Managing Member
           
     

    Dr. Jeffrey R. Jay, M.D.

           
      By:  /s/ Dr. Jeffrey R. Jay, M.D.
        Dr. Jeffrey R. Jay, M.D.
           
     

    Mr. Ortav Yehudai

           
      By:  /s/ Mr. Ortav Yehudai
        Mr. Ortav Yehudai
           

     

     
    CUSIP No. N44821101
     SCHEDULE 13G/A
    Page 9 of 9 Pages

    Exhibit A

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned hereby agree as follows:

     

    (i) Each of them is individually eligible to use the Schedule 13G/A to which this Exhibit is attached, and such Schedule 13G/A is filed on behalf of each of them; and

     

    (ii) Each of them is responsible for the timely filing of such Schedule 13G/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2022

     

     

    Great Point Partners, LLC

           
      By:  /s/ Dr. Jeffrey R. Jay, M.D.
        Dr. Jeffrey R. Jay, M.D., as Senior Managing Member
           
     

    Dr. Jeffrey R. Jay, M.D.

           
      By:  /s/ Dr. Jeffrey R. Jay, M.D.
        Dr. Jeffrey R. Jay, M.D.
           
     

    Mr. Ortav Yehudai

           
      By:  /s/ Mr. Ortav Yehudai
        Mr. Ortav Yehudai
    Get the next $IFRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IFRX

    DatePrice TargetRatingAnalyst
    5/29/2025$2.00Strong Buy → Outperform
    Raymond James
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/5/2023$8.00Neutral → Buy
    Guggenheim
    2/28/2022Buy → Neutral
    Guggenheim
    11/8/2021$14.00 → $15.00Strong Buy
    Raymond James
    10/28/2021$14.00Outperform → Strong Buy
    Raymond James
    8/6/2021$11.00 → $10.00Outperform
    Raymond James
    8/6/2021$2.80 → $2.50Underperform
    Credit Suisse
    More analyst ratings

    $IFRX
    SEC Filings

    View All

    SEC Form 6-K filed by InflaRx N.V.

    6-K - InflaRx N.V. (0001708688) (Filer)

    8/7/25 8:12:58 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by InflaRx N.V.

    6-K - InflaRx N.V. (0001708688) (Filer)

    7/14/25 4:15:19 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by InflaRx N.V.

    6-K - InflaRx N.V. (0001708688) (Filer)

    6/27/25 4:05:32 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $IFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InflaRx Announces Participation in September Investor Conferences

    JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2025. Details are as follows: Cantor Global Healthcare Conference 2025September 3 - 5, 2025 in New York, NYFireside chat on September 4th at 9:10 AM ET InflaRx will also conduct one-on-one investor meetings on September 4th. A link to view the fireside chat live stream and its replay is available here. H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 8 - 10, 2025 in New York, NYPresentation on September 9th at 3:30

    8/21/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

    INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals for InflaRx-partnered C5a antibody BDB-001 in ANCA-associated vasculitis (AAV) were favorable, with Staidson expecting Phase 3 study initiationInflaRx working diligently toward unblinding of stopped Phase 3 pyoderma gangrenosum (PG) trial so that all data can be analyzed later this yearEnrollment began in BARDA funded JUST BREATHE Phase 2 platform clinical trial investigating vilobelimab and additional novel therapeutic candidates for acute respiratory distress syndrome (ARDS)Cash, cash equ

    8/7/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx to Report Second Quarter 2025 Results on August 7, 2025

    JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powe

    7/31/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx downgraded by Raymond James with a new price target

    Raymond James downgraded InflaRx from Strong Buy to Outperform and set a new price target of $2.00

    5/29/25 8:15:13 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on InflaRx with a new price target

    Cantor Fitzgerald initiated coverage of InflaRx with a rating of Overweight and set a new price target of $10.00

    4/29/25 8:10:45 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx upgraded by Guggenheim with a new price target

    Guggenheim upgraded InflaRx from Neutral to Buy and set a new price target of $8.00

    4/5/23 11:33:25 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Financials

    Live finance-specific insights

    View All

    InflaRx to Report Second Quarter 2025 Results on August 7, 2025

    JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powe

    7/31/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx to Report First Quarter 2025 Results on May 7, 2025

    JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory media

    4/30/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

    JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned. InflaRx also announced that it will participate in two investor conferences. Details are as follows: Leerink Global Healthcare ConferenceMarch 9 - 12, 2025 in Miami Beach, FL InflaRx will conduct a fireside chat at the conference on March 10 at 10:40 AM ET and will participate in one-on-one-investor meetings. A link to regis

    2/25/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InflaRx N.V.

    SC 13G - InflaRx N.V. (0001708688) (Subject)

    4/24/23 4:47:08 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by InflaRx N.V.

    SC 13G - InflaRx N.V. (0001708688) (Subject)

    4/17/23 4:00:10 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by InflaRx N.V. (Amendment)

    SC 13G/A - InflaRx N.V. (0001708688) (Subject)

    2/13/23 12:01:42 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Leadership Updates

    Live Leadership Updates

    View All

    InflaRx Appoints Jan Medina as Head of Investor Relations

    JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx. Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: "We are delighted to welcome Jan to our team. His experience, proven track record and deep network with investors and capital mark

    2/22/24 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

    Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug developmentDr. Chong to lead clinical development of InflaRx's portfolio of C5a/C5aR inhibitors JENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry, including leadership roles in clinical development, medical affai

    6/28/23 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care